Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorambucil vs Rituximab vs Combination in MALT Lymphoma
NCT00210353Phase 3Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Jan 2003
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of rituximab in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (3 arms), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: Event-free-survival at 5 years. Started Jan 2003; status: completed.
02
Drugs
rituximab
03
Conditions
extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Beyond the preview
Go deeper on NCT00210353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210353.